Pharmacodynamics of carvedilol in conscious, healthy dogs

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 297-304

  Gordon, Sonya G ^a   Arsenault, Wendy G ^a,d   Longnecker, Mike ^b   Boothe, Dawn M ^a,c   Miller, Matthew W ^a   Chalkley, Jeff ^e  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c AUBURN UNIVERSITY   (United States)

^d Southwest Florida Veterinary Cardiology   (United States)

^e KANSAS STATE UNIVERSITY   (United States)

Author keywords

Beta blocker; Cardiology; Carvedilol; Drug therapy; Isoproterenol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONSCIOUSNESS; DOG; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HEART RATE; MALE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARBAZOLES; CONSCIOUSNESS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; MALE; PROPANOLAMINES;

CANIS FAMILIARIS;

EID: 33645235451     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[297:POCICH]2.0.CO;2     Document Type: Article

References (19)

1. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade on chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
2. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-2648.
3. Eichhorn E, Bristow M. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794-798.
4. Urabe Y, Mann D, Kent R, et al. Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation. Circ Res 1992;70:131-147.
5. Ware W, Lund D, Subieta A, et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990;197:1475-1481.
6. Starling M. Emerging biology of mitral regurgitation: Implications for further therapy. Adv Cardiol 2002;39:15-23.
7. Mann D, Kent R, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
8. Morgan T, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol 1987;10:124-129.
9. Bristow M. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569.
10. Poole-Wilson P. Commentary on the carvedilol or metoprolol European trial (COMET). Am J Cardiol 2004;93(9A):40B-42B.
11. Schaefer W, Politowski J, Hwang B, et al. Metabolism of carvedilol in dogs, rats, and mice. J Met Disp 1998;26:958-969.
12. Sawangkoon S, Miyamoto M, Nakayama T, et al. Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. Am J Vet Res 2000;61:57-60.
13. Uechi M, Sasaki T, Ueno K, et al. Cardiovascular and renal effects of carvedilol in dogs with heart failure. J Vet Med Sci 2002;64:469-475.
14. Abbott J, Broadstone R, Pyle R. Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. Am J Vet Res 2005;66:637-641.
15. Yamakawa H, Takeuchi M, Takaoka H, et al. Negative chronotropic effect of β-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation 1996;94:340-345.
16. McTavish D, Campoli-Richards D. Sorkin EM. Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;45:232-258.
17. Neugebauer G, Akpan W, Mollendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10:85-88.
18. Bristow M, Gilbert E, Abraham W, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
19. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am J Cardiol 2000;85:1495-1497.